execut turnov omega integr issu
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
valuat growth profit
methodolog valu compani
recent post better result follow weak
stem omega integr issu return brand
competitor like johnson johnson store shelv
competit pressur compani prescript topic
busi previous consid store-brand
market share gain competitor manufactur issu
consum seek lower-cost option recess
unsustain think oper sustain
reason growth even though expect
reset execut turnov remain concern think
resili consum health busi sustain stabl
long term think consum health busi support
steadi growth littl risk reimburs concern
new entrant increas peer like teva
becom focus space on-going market penetr
private-label product intern portfolio expans
over-the-count approv exist prescript drug
help bolster growth prescript segment also
primari driver growth margin expans although
think segment support above-averag profit
prescript topic busi shrunk increas competit
omega deal under-perform tarnish manag
merger acquisit streak still think
compani capital-alloc decis enhanc competit
advantag long-term growth opportun recent omega
acquisit make major player european over-the-counter
market provid necessari brand portfolio salesforc
compet among fragment custom base retail
region acquisit
food drug administration-approv private-label infant
formula manufactur sergeant boost access
store-brand pet-car market unlik over-the-counter drug store-brand
penetr market remain rel small perrigo
like leverag store-brand retail expertis expand
categori
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
largest store-brand over-the-count pharmaceut
pharmaceut activ pharmaceut ingredi unit
state sell product stock-keep unit
follow acquisit omega pharma approxim
compani revenu come outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit may
lower fair valu estim per share
although recent result mostli match
expect reduc near-term forecast
follow announc anoth delay fda
approv firm gener version teva proair
may fall middl later fair
valu estim impli forward price-to-earnings multipl
growth fuel mid-single-digit growth
consum health nutrit segment combin
return low-single-digit growth prescript drug
segment follow declin revenu
volum face pressur competit over-the-counter
market modestli intensifi market share gain
store-brand product slow econom condit stabil
reduct sale certain under-perform non-core
asset help stabil profit
dont anticip major futur margin expans
compani consum health nutrit prescript
drug segment probabl continu reli
omega salesforc distribut infrastructur
expand oper throughout europ tax manufactur
administr area offer long-term potenti cost
companywid oper margin eventu rise
back high teen next year
compani make improv integr omega
estim long-term corpor tax rate
remain near assum cost capit
approxim compani
despit rel stabil private-label
consum health busi assign firm high
uncertainti rate due recent volatil gener
prescript topic segment on-going issu
integr omega sale tysabri royalti
remov uncertainti compani futur cash
bull case assum continu share gain
gener over-the-counter market larger new product launch lead
five-year averag organ growth consum
health segment also includ intern sale
growth brand prescript pharmaceut
segment stock price per share scenario
reach oper margin thank
success integr omega better-than-expect
contrast bear-cas scenario assum slow custom
accept store-brand
weak prescript topic busi
greater-than-expect competit price pressur
gener over-the-counter market model low-single-digit growth
across consum health segment nearli zero
growth prescript segment bear-cas
scenario yield fair valu estim per share
chang moat rate none
narrow consid gener drug industri
whole predominantli no-moat industri includ
barrier entri remain low product remain highli
commodit industri remain fairli fragment
despit past consolid consum health
oper previous thought economi
scale shelf space manag uniqu packag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
topic market like continu diminish firm
histori stabl price segment
capabl help entrench firm custom suppli
chain addit thought manufactur
regulatori barrier prescript topic segment
could support above-averag growth profit
think continu rise new entrant particularli
low-cost emerg market continu diminish cost
advantag larger peer like given recent price
eros prescript topic unit combin
poor perform omega asset diminish
confid creat econom profit
long term abil challeng gradual
improv growth profit seen much
recent past probabl difficult sustain
acquisit tysabri royalti histor
made larg portion bottom line
manag sold asset earli
think neg econom moat trend
think rel larg exposur over-the-counter gener
drug market threaten erod firm cost advantag
time addit new competit prescript
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
odifficult econom condit push price-
ojohnson johnson return over-the-counter market
gradual improv economi slow
market share gain store-brand segment
market leader gener releas
prescript drug receiv over-the-counter approv
particip major domest launch
see less sever competit price
pressur topic segment gener drug
industri addit one fourth
gener drug applic first-to-fil statu
grant day market exclus ensur
depress return capit acquisit
live expect overpay asset
remain credibl threat sharehold
recent deal help diversifi
oper major retail
repres larg concentr
revenu give compani littl price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
like mani peer specialti pharma industri
appetit acquisit increas financi
leverag year believ cash flow
enabl compani meet financi oblig
includ small dividend gradual reduc debt
burden billion acquisit omega
billion acquisit follow number smaller deal
like sergeant paddock lab
past year push total debt close billion
end recent manag reduc
financi leverag compani sold tysabri
royalti stream billion cash million
net debt/ebitda time
estim fall base current
perform announc acquisit
possess consolid custom base
among larg consolid retail chain wholesal
acquisit omega pharma boost
diversif alon account almost
revenu follow combin omega although
undoubtedli firmli embed custom
suppli chain unlik shift anoth supplier would
disastr consequ low-cost
emerging-market competitor abl
success compet higher-valu
store-brand over-the-counter market dont predict drastic shift
market share medium term earli
manag sold tysabri royalti stream
repres signific portion compani cash
flow face new competit product like
ocrelizumab near term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
give standard stewardship rate
papa leav run valeant follow
exit cfo judi brown ceo john hendrickson
announc retir middl uwe
roehrhoff began role ceo earli
hendrickson join extens
leadership experi compani roehrhoff bring
year leadership experi gerresheim ag
work sinc ron winowiecki also
switch interim perman cfo earli
winowiecki variou finance-rel
papa tenur ceo chairman manag
made mostli wise capital-alloc decis
opinion recent paddock lab pbm hold
acquisit came fair price broaden
moat give compani stronghold
high-barrier-to-entri infant nutrit topic drug
market recent deal lower
compani tax rate omega expand oper
europ also help improv competit advantag
concern acquisit could perman
erod return capit dont expect return capit
return compani histor norm anytim soon
under-perform lead impair end
suggest manag may bitten
could chew recent deal
view mostli shareholder-friendli firm
appreci portion
compens stem partial return capit
seper ceo chairman board role
time independ director lauri brla
member board sinc becam
chairman board
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first quarter keep year-end perform
dont anticip chang fair valu estim
compani first-quart result keep
compani track year-end forecast
manag maintain year-end outlook
incorpor slight out-performance intern
consum health busi off-set slightli
regardless overal perform continu
mostli meet expect new product includ
potenti fourth-quart launch gener proair
repres on-going improv compani
leav no-moat rate place
prescript
constant currenc growth basi point
oper margin expans last year product
volum domest consum health oper remain
stabl perform segment -- trend expect
continu manag note strength infant nutrit
season strong cough cold sale off-set
partial weak anim health delay
flea tick season
particularli strong oper margin expans nearli
basi point larg product mix new
launch restructur effort manag
anticip invest segment remaind
year suppress recent profit gain still think
manag initi effici initi
product geograph
focu sustain
prescript segment continu face
challeng thank on-going issu gener industri
suppli disrupt recent launch product
potenti limited-competit launch gener proair
fourth quarter help uphold perform
gener proair place expect
billion segment sale year final quarter
account approxim addit ep
year immun pressur
custom consolid increas competit
gener industri segment profitabilitywhich
declin basi point last year higher oper
cost despit improv gross margincontinu
track expect sale segment
quarter
perrigo outlook suggest stabil amid over-the-counter
dont plan alter fair valu estim no-moat
rate make adjust
match expect manag outlook
incorpor lower-than-expect growth
domest consum health segment off-set growth
intern consum
prescript segment new product launch
teva proair boost growth profit
back half year despit segment differ
forecast billion revenu adjust
ep fall midpoint top end manag
industrywid pressur over-the-count over-the-counter
market weve heard brand consum health
compani includ store closur slow
domest consum health busi think
recent store-brand nexium launch private-
label portfolio sustain above-market growth
addit partnership amazon remain
modest net posit view despit risk in-
store cannib adjust oper margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
quarter continu thank product
mix oper effici reflect healthi
busi view
turnaround intern consum health
prescript segment also seem steadi exclud
divestitur growth intern busi
segment-adjust oper margin
continu reflect oper improv addit
higher product complex new product launch
prescript topic busi report
growth exclud entocort competit
adjust oper margin quarter help
insul compani broader price pressur
delay earn releas feb
limit fourth-quart result
manag delay releas final year-end earn
allow addit time review incom tax procedur
non-cash item compani attain year-end net
sale billion million oper
incom billion adjust oper incom
gener match expect furthermor billion
billion million america consum
health intern consum healthi prescript
gener segment respect fell line
forecast compani disclos outlook
base initi result dont plan chang
fair valu estim although think
label consum health topic gener
oper continu help insul compani
broader competit buyer pressur affect
gener drug industri still dont think compani earn
econom moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
